ReviewCancer control : journal of the Moffitt Cancer Center
KIAA1199: A Novel Regulator of Chemoresistance in Human Cancer Cells.
Review in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
KIAA1199 (also known as CEMIP or HYBID), an archived gene listed in the Human Unidentified Gene-Encoded (HUGE) database, has been implicated in tumor progression and metastasis in a wide range of cancers, including breast, cervical, cholangiocarcinoma, pancreatic, colorectal, gastric, hepatocellular, lung, ovarian, prostate, papillary thyroid, and brain cancers. Overexpression of KIAA1199 is significantly correlated with poor prognosis and metastasis and has been clinically associated with chemoresistance. In addition, KIAA1199 may serve as a novel biomarker for cancer diagnosis and prognosis, particularly due to its role in maintaining cancer stem cell properties. However, the molecular mechanisms by which KIAA1199 regulates chemoresistance, prognosis, and cancer stem cell development remain incompletely understood. Therefore, this review aims to summarize the clinical relevance of KIAA1199 as a novel regulator involved in chemoresistance, cancer prognosis, and cancer stem cell biology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.